(Report ID: 93081) Many drug interactions and side effects can not be detected until the drugs have been used by millions of people, and for a long time. Large, long-term drug safety studies are ideal to discover these real-world drug outcomes. For the first time, eHealthMe enables health professionals and patients to conduct these studies for their drugs. Click here to check your drugs now, in a whole new way. As of Nov, 20, 2008, eHealthMe analyzes 10,180,594 drug interactions and side effects of 21,667 FDA-approved drugs from 1977 to the present. Results on Nov, 20, 2008: 8 relevant incidents
Note:
- The incidents can not include all actual occurrences
- Data of 2008 is not complete
DISCLAIMER: All adverse drug reaction material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk. Basic information:
| Report ID | Date of submission | Patient age | Patient gender |
| 93081 | Mar, 31, 2006 | Not specified | Male |
List of drugs the patient takes:
| Drug |
Rebif |
Amantadine Hcl |
Fluoxetine Hydrochloride |
List of drug interactions, adverse side effects / events the patient has:
Results from eHealthMe: 8 relevent incidents1) Comparison with the patient's adverse outcomes:
| Name | Count (% of total reports) |
Convulsion | 3 (37.50%) |
Syncope | 1 (12.50%) |
2) Top drug interactions, adverse side effects reported for the past 12 months:Death: 0 Cancer: 0
| Name | Count (% of total reports) |
1 | Tic | 1 (100.00%) |
2 | Tremor | 1 (100.00%) |
3 | Multiple Sclerosis Relapse | 1 (100.00%) |
4 | Feeling Abnormal | 1 (100.00%) |
5 | Aspartate Aminotransferase Increased | 1 (100.00%) |
6 | Alanine Aminotransferase Increased | 1 (100.00%) |
3) Top co-used drugs drugs reported for the past 12 months:
| Name | Count |
1 | Mirapex | 1 |
2 | Keppra | 1 |
3 | Provigil | 1 |
4 | Ambien | 1 |
4) Top drug interactions, adverse side effects reported of all time:Death: 0 Cancer: 0
| Name | Count (% of total reports) |
1 | Convulsion | 3 (37.50%) |
2 | Tremor | 3 (37.50%) |
3 | Mania | 2 (25.00%) |
4 | Eye Rolling | 2 (25.00%) |
5 | Memory Impairment | 2 (25.00%) |
6 | Movement Disorder | 2 (25.00%) |
7 | Blood Cholesterol Increased | 2 (25.00%) |
8 | Depressed Level Of Consciousness | 2 (25.00%) |
9 | Incoherent | 2 (25.00%) |
10 | Myocardial Ischaemia | 2 (25.00%) |
5) Top co-used drugs drugs reported of all time:
| Name | Count |
1 | Prozac | 3 |
2 | Wellbutrin | 3 |
3 | Clonazepam | 2 |
4 | Aspirin | 2 |
5 | Avonex | 2 |
6 | Oxybutynin Chloride | 2 |
7 | Loratadine | 2 |
8 | Venlafaxine Hcl | 1 |
9 | Hydroxyzine Hcl | 1 |
10 | Ambien | 1 |
Want to have a risk analysis report like this for your drugs? Click here. ADVERTISEMENT
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Recent drug risk analysis reports:
Side effects comparison of Cozaar (Merck) - 25MG (Nov, 20, 2008)
|
Metoprolol Tartrate (Aurobindo Pharma... for ... (Nov, 20, 2008)
|
Strattera (Lilly) - 40MG for ... (Nov, 20, 2008)
|
Tamoxifen Citrate (Aegis Pharms) - EQ... for Breast Cancer (Nov, 20, 2008)
|
Side effects comparison of Remicade (Centocor Inc) - 100MG (Nov, 20, 2008)
|
Xanax (Pharmacia And Upjohn) - 0.5MG for Stress And Anxiety (Nov, 20, 2008)
|
Carisoprodol (Watson Labs) - 350MG for Pain - Back (Nov, 20, 2008)
|
Side effects comparison of Zoloft (Pfizer) - EQ 200MG BASE (Nov, 20, 2008)
|
Lomotil for Diarrhea (Nov, 20, 2008)
|
Side effects comparison of Nicotine Polacrilex (Perrigo R And D)... (Nov, 20, 2008)
|
|
|
|
 |
|
How to use the report?
Bring a copy of this report to a doctor's appointment to ensure drug risks are fully discussed and understood, in the process of risk and benefit assessment.
|
 |
|
ADVERTISEMENT
|
|